CapTemY90 for Grade 2/3 NET Liver Metastases

This study is testing a triple-therapy approach for people with neuroendocrine tumors (slow-growing cancers that often start in the gut or pancreas) that have spread to the liver and cannot be removed by surgery. The combination includes two oral chemotherapy drugs (capecitabine and temozolomide) and a liver-targeted radiation therapy called Y-90 radioembolization, which delivers radiation directly to liver tumors via tiny beads. **You may be eligible if...** - You are 18 years or older - You have a confirmed grade 2 or 3 well-differentiated neuroendocrine tumor with liver metastases that cannot be surgically removed - At least half of your total cancer burden is in the liver - You have at least one liver tumor larger than 1 cm - Your liver tumor burden does not exceed 50% of total liver volume - Your liver, blood, and kidney function meet minimum requirements - You have a life expectancy greater than 6 months **You may NOT be eligible if...** - You have previously had liver embolization or Y-90 radioembolization - You are allergic to capecitabine or temozolomide - You cannot have both MRI and CT scans - You are pregnant Talk to your doctor to see if this trial is right for you.